Nanjing Luye Pharma

Nanjing Luye Pharmaceutical is a leading oncology-focused pharmaceutical company based in China and a key subsidiary of the Luye Pharma Group. The company is recognized for its expertise in advanced drug delivery systems, specifically liposomal and microsphere technologies, which it uses to develop differentiated formulations of established and novel therapies. Its flagship product, Lipusu (paclitaxel liposome), is a market-leading chemotherapy agent in China for various solid tumors and represents the first liposomal paclitaxel product globally. Nanjing Luye also holds the rights to commercialize Zepzelca (lurbinectedin) in China and is advancing a pipeline of liposomal and microsphere-based candidates for small cell lung cancer and other high-unmet-need indications. The company operates integrated R&D and manufacturing facilities in Nanjing that adhere to international GMP standards.